Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacological and Regulatory Aspects of QT Prolongation

European Procedures at the Italian Medicines views of the Italian Medicines Agency. [Pg.55]

Copyright 2008 WILEY-VCH Verlag GmbH Co. KGaA, Weinheim ISBN 978-3-527-31821-6 [Pg.55]

Localization/Expression Function/Pathophysiology Target (Desired Effect) Antitarget (Side Effect) [Pg.56]

Myocardium Cardiac action potential Class III antiarrhythmics block hERG Many noncardiac drugs block [Pg.56]

Neurons Does it contribute to the sudden death phenotype associated with LQT2 syndrome Several functions [11] Antiepileptic drugs Side effects of hERG blockers [Pg.56]

See other pages where Pharmacological and Regulatory Aspects of QT Prolongation is mentioned: [Pg.55]    [Pg.56]    [Pg.58]    [Pg.60]    [Pg.62]    [Pg.64]    [Pg.66]    [Pg.68]    [Pg.70]    [Pg.72]    [Pg.74]    [Pg.76]    [Pg.78]    [Pg.80]    [Pg.82]    [Pg.84]    [Pg.86]    [Pg.88]    [Pg.157]    [Pg.55]    [Pg.56]    [Pg.58]    [Pg.60]    [Pg.62]    [Pg.64]    [Pg.66]    [Pg.68]    [Pg.70]    [Pg.72]    [Pg.74]    [Pg.76]    [Pg.78]    [Pg.80]    [Pg.82]    [Pg.84]    [Pg.86]    [Pg.88]    [Pg.157]    [Pg.248]    [Pg.55]    [Pg.13]   


SEARCH



Pharmacological aspects

Pharmacology of QT Prolongation

Prolong

Prolonged

QT prolongation

QT prolongers

Regulatory Aspects of QT Prolongation

© 2024 chempedia.info